Press Releases

NASDAQ Copenhagen A/S

Partnership combines Evyve's sustainable charging leadership with Tritium's industry-first lifetime 

(Oslo, Norway, 22 July 2025) – Statkraft delivered strong operational performance in the second quarter of 2025, despite lower prices, especially in the northern price areas of Norway and Sweden. Net results were negatively impacted by impairments, mostly due to lower estimated future power prices in certain regions, and currency effects. Statkraft continues to refocus for profitable growth.

Pärast peaaegu kahekümne aasta kestnud edukat äritegevust Bulgaaria kinnisvaraturul on Arco Vara AS juhatus alustanud strateegilist väljumisprotsessi, mille lõppeesmärgiks on ettevõtte täielik lahkumine Bulgaaria turult. Otsuse kinnitas 2025. aasta juulis ettevõtte nõukogu, kes hindas põhjalikult Arco Vara pikaajalist strateegiat ning seniseid ja tulevasi arenguvõimalusi erinevatel turgudel.

(Oslo, 22. juli 2025) – Statkraft leverte sterkt driftsresultat i andre kvartal 2025, tross lavere priser, spesielt i de nordlige prisområdene i Norge og Sverige. Resultatet ble negativt påvirket av nedskrivninger, hovedsakelig på grunn av forventinger om lavere kraftpriser i enkelte regioner, samt valutaeffekter. Statkraft refokuserer for fortsatt lønnsom vekst.

After nearly twenty years of successful business activity in the Bulgarian real estate market, the Management Board of Arco Vara AS has initiated a strategic exit process, with the ultimate goal of a complete withdrawal from the Bulgarian market. The decision was confirmed by the company’s Supervisory Board in July 2025, following a thorough evaluation of Arco Vara’s long-term strategy and the current and future development opportunities across different markets.

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgennemgang, hvilket potentielt understøtter godkendelse af vaccinen i første halvår 2026.